HUMAN MYELOID DERIVED SUPPRESSOR CELL CANCER MARKERS

WIPO Patent Application WO/2012/149416

A3

Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33+/HLA-DRlow, CD14+/HLA-DRlow, CD66b+/HLA-DRlow or, CD11b+/HLA-DRlow MDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1α, or C/EBPβ. The MDSC phenotype can be CD33+HLA-DRlowHIF1α+/STAT3+, CD14+HLA-DRlow HIF1α +/ STAT3+ / pSTAT3+ /C/EBPb+, CD66b+HLA-DRlow HIF1α+/ STAT3+ / pSTAT3+ /C/EBPb+, CD33+HLA-DRlow HIF1α+/ STAT3+ / pSTAT3+ /C/EBPb+, CD11b+HLA-DRlow HIF1α+/ STAT3+ / pSTAT3+ /C/EBPb+, or CD11b+HLA-DRlowC/EBPβ+. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.

EPSTEIN ALAN L (US)
LECHNER MELISSA G (US)

PCT/US2012/035586

January 10, 2013

April 27, 2012

Click for automatic bibliography generation  

UNIV SOUTHERN CALIFORNIA (US)
EPSTEIN ALAN L (US)
LECHNER MELISSA G (US)

A61K38/16; A61K38/17; A61K39/395; A61K48/00; A61P35/00

WO2010055340A1	2010-05-20
WO2010062990A1	2010-06-03

US20110059106A1

2011-03-10

MELISSA. G. LECHNER ET AL.: "Characterization of Cytokine-Induced Myeloid- Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells.", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 4, 15 August 2010 (2010-08-15), pages 2273 - 2284, XP055015017

KONSKI, Antoinette, F. et al. (975 Page Mill RoadPalo Alto, California, US)

View/Download PDF      PDF Help

Previous Patent: REMOTE ADJUSTMENT OF A ROW UNIT OF AN AGRICULTURAL DEVICE

Next Patent: BRACHYTHERAPY DEVICE AND METHOD